This preprint is under consideration at Medical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Nan Wu
Jiangsu Cancer Hospital;Jiangsu Institute of Cancer Research; the affiliated cancer hospital of Nanjing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0942-5278
License:
This work is licensed under a CC BY 4.0 License. Read Full License
To identify molecular features related to immunogenic activity in breast cancer (BC) and provide new targets and directions for BC immunotherapy. We first used ESTIMATE to evaluate the degree of immune cell infiltration of the BC patients in TCGA and METABRIC, and explore the relationship between the degree of immune cell infiltration and prognosis of breast cancer patients. Then, we identified the cancer pathways, proteins, miRNAs related to BC immunogenicity, and predicted miRNAs target genes and identified the pathways related to target genes with KEGG pathway enrichment analysis. We also explored the correlation between PD-L1 expression level and cancer pathways and found that PD-L1 expression showed a positive association with cancer pathways. In this article we have successfully identified several cancer pathways, proteins, miRNAs and their target genes, which could be as promising new target for BC immunotherapy. And PD-L1 blockade therapy may be more effective in BC patients with the activation of some cancer pathways.
Keywords
breast cancer, tumor immunity, immunotherapy, miRNA, PD-L1
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 Feb, 2021
No community comments so far
Editorial decision: Minor Revisions Needed
On 22 Mar, 2021
Reviews received
Received 28 Feb, 2021
Reviewers invited
Invitations sent on 13 Feb, 2021
Editor assigned
On 03 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This preprint is under consideration at Medical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Nan Wu
Jiangsu Cancer Hospital;Jiangsu Institute of Cancer Research; the affiliated cancer hospital of Nanjing Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0942-5278
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 Feb, 2021
No community comments so far
Editorial decision: Minor Revisions Needed
On 22 Mar, 2021
Reviews received
Received 28 Feb, 2021
Reviewers invited
Invitations sent on 13 Feb, 2021
Editor assigned
On 03 Feb, 2021
First submitted
On 27 Jan, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
To identify molecular features related to immunogenic activity in breast cancer (BC) and provide new targets and directions for BC immunotherapy. We first used ESTIMATE to evaluate the degree of immune cell infiltration of the BC patients in TCGA and METABRIC, and explore the relationship between the degree of immune cell infiltration and prognosis of breast cancer patients. Then, we identified the cancer pathways, proteins, miRNAs related to BC immunogenicity, and predicted miRNAs target genes and identified the pathways related to target genes with KEGG pathway enrichment analysis. We also explored the correlation between PD-L1 expression level and cancer pathways and found that PD-L1 expression showed a positive association with cancer pathways. In this article we have successfully identified several cancer pathways, proteins, miRNAs and their target genes, which could be as promising new target for BC immunotherapy. And PD-L1 blockade therapy may be more effective in BC patients with the activation of some cancer pathways.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Loading...